Expert Opin Pharmacother. 2002 Jul;3(7):979-91.

Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Pearlstein T,Yonkers KA.

Women's Behavioural Health Program, Women and Infants Hospital, 101 Dudley Street, Providence, RI 02905-2499, USA.

Teri-Pearlstein@brown.edu

The largest number of antidepressant treatment trials in premenstrual syndrome and premenstrual dysphoric disorder (PMDD) have been conducted with fluoxetine. Fluoxetine and other selective serotonin re-uptake inhibitors (SSRIs) clearly reduce premenstrual emotional and physical symptoms and improve premenstrual psychosocial functioning. Fluoxetine was the first SSRI to be approved by the FDA as a treatment for the emotional and physical symptoms of PMDD. Fluoxetine 20 mg has been reported to be effective for emotional and physical premenstrual symptoms with continuous daily dosing (every day of the menstrual cycle) and with luteal phase daily dosing (from ovulation to menses). In addition, premenstrual emotional symptoms have been reported to improve with fluoxetine 10 mg in luteal phase daily dosing and with 90 mg 2 and 1 weeks prior to menses. Fluoxetine is generally a well-tolerated treatment for PMand discontinuation effects have not been reported with intermittent dosing regimens.


Women's Health



women's health


Please click on the required question.

Women's Health

Thank you for choosing to visit us.


This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London - Specialist Interests - Reproductive Medicine including Infertility, PCOS, PMS, Menopause and HRT.

I do hope that you find the answers to your women's health questions in the patient information and medical advice provided.





Keyword SEO Pro



Single Page

SEO Videos